MediSieve公司研制磁性血液过滤器。针对疟疾治疗，从患者血液中去除病原体、毒素等来治疗血液传播疾病。

 主要客户：包括美国、亚洲、非洲和南美洲的公共和私人医院。

目标市场：疟疾影响最严重的国家是印度、加纳和尼日利亚。

销售产品：产品预计将在2019年完成, 可针对疟疾，2021 年针对白血病， 2022年达到针对败血症的功用。

MediSieve is an early stage medical device  company developing “magnetic blood filtration” which is a revolutionary  method of treating blood-borne diseases by removing pathogens, toxins, or  other targets directly from a patient’s bloodstream. Its R&D is focused  on malaria, leukaemia, and sepsis.

MediSieve是一家开发“磁性血液过滤器”的早期医疗器械公司，该公司的革命性治疗方法是通过直接从患者血液中去除病原体、毒素或其他靶向来治疗血液传播疾病。他们的研发重点是疟疾，白血病和败血症。该公司于2015年5月从伦敦大学学院的spin-out项目，筹集了35万美元的种子投资和25万英镑的拨款支持。

MediSieve is an early stage medical device company  developing “magnetic blood filtration” which is a revolutionary method of  treating blood-borne diseases by removing pathogens, toxins, or other targets  directly from a patient’s bloodstream. Its R&D is focused on malaria,  leukaemia, and sepsis. MediSieve emerged from University College London in May  2015, raising GBP 350,000 in seed investment and GBP 250,000 in grant support  in the same year.